UNSPSC 51383404: Proglumetacin

This classification denotes an indoleacetic acid and non-steroidal anti-inflammatory agent with the molecular formula C46H58ClN5O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FV919079LU, chemically known as 3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl dl-4-benzamido-n,n-dipropylglutaramate 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetate (ester) but generally known as proglumetacin, which bears US NIH Compound Identifier 4921.

UNSPSC 51383404 Proglumetacin is a Commodity code that nominally names a specific anti-inflammatory pharmaceutical agent, but recent state and local opportunities tagged under it diverge substantially from that narrow scope. The three most recent solicitations show state and local governments procuring naloxone and drug deactivation systems, therapeutic pharmacy initiative vendor capabilities, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements. The actual buying under this code spans pharmaceutical procurement, including both branded and generic drugs, naloxone kits, and OTC products distributed through authorized wholesalers or community health programs. Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions; Seminole County, Florida; Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) all posted opportunities in the past four months.

Recent activity concentrates in the Southeast and Upper Midwest. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries by July 26, 2023 (note: deadline date appears inconsistent with posting date), with a two-year initial term and one-year renewal option, requiring E-Verify compliance and drug-free workplace certification. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to solicit vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager relationships, representing an exploratory phase before formal RFP issuance. MMCAP, administered by Minnesota's Office of State Procurement and serving participating jurisdictions including Oregon, issued RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson), with awarded vendors effective July 1, 2026; awards will be weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on format compliance, EDI capability, and administrative fee agreement.